Lilly’s Mirikizumab Hits All Marks In First Phase III Study For UC

Antibody targeting IL-23p19 yields clinical remission of ulcerative colitis after 12 weeks in the Phase III LUCENT-1 study. It also met all secondary endpoints, including reduction of bowel urgency.

Lilly gets positive Phase III data for its anti-IL-23 candidate in ulcerative colitis

Eli Lilly and Company’s development plans for mirikizumab took another step forward on 16 March as the pharma unveiled top-line data from the Phase III LUCENT-1 trial showing that the interleukin 23 (IL-23) blocker provided clinical remission of ulcerative colitis at 12 weeks and also hit all of the study’s secondary endpoints.

In the large induction study, mirikizumab met statistical significance for clinical remission – control or resolution of inflammation of the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D